Development and characterization of polymeric-based nanoparticles for sustained release of amoxicillin – an antimicrobial drug
Source abstract
Abstract
In this study, amoxicillin (AMO)-loaded poly(vinyl alcohol)/sodium alginate (PVA/NaAlg) nanoparticles were prepared as a polymer-based controlled release system. The physicochemical properties of the obtained nanoparticles were investigated by XRD, DSC/TGA, particle size analyses and zeta potential measurements. The average particle sizes were in the range from 336.3 ± 25.66 to 558.3 ± 31.39 nm with negative zeta potential values from -41.86 ± 0.55 to -47.3 ± 2.76 mV. The influences of PVA/NaAlg ratio, span 80 concentration, exposure time to glutaraldehyde (GA) and the drug/polymer ratio on AMO release profiles were evaluated. In vitro drug release studies showed a controlled and pH dependent AMO release with an initial burst effect. XRD patterns and DSC thermograms of AMO-loaded nanoparticles revealed that the drug in the nanoparticles was in amorphous form, which was more stable than the crystalline form. The antibacterial activity of the optimal formulation was also investigated. The minimum inhibitory concentration (MIC) values of this formulation had the comparable antibacterial activity with that of pure AMO. These results indicate that the developed nanoparticles could be a promising candidate drug delivery system for AMO.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Advancements in Transdermal Drug Delivery · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Kırıkkale University
Department of Chemistry, Faculty of Science and Arts, Kırıkkale University
Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Istanbul University
Department of Microbiology, Faculty of Veterinary Medicine, Kırıkkale University
Funding
Department of Scientific Research Projects, Istanbul University
References (57)
Show source-provided references
1. 10.1201/b11374-1210.1201/b11374-12 ↗
2. 10.3390/ijms1809183610.3390/ijms18091836 ↗
3. Singh M, Hemant K, Ram M, et al. Microencapsulation: a promising technique for controlled drug delivery. Res Pharm Sci. 2010;5:65–77.
4. Bhowmik D, Gopinath H, Kumar BP, et al. Controlled release drug delivery systems. The Pharma Innovation. 2012;1:24–32.
5. 10.1016/j.ces.2014.08.04610.1016/j.ces.2014.08.046 ↗
6. Lee J. Nanoparticle-assisted controlled drug release. J Nanomedine Biotherapeutic Discov. 2014;4:1–2.
7. 10.2174/138920101766616012711044010.2174/1389201017666160127110440 ↗
8. 10.1016/j.matlet.2016.05.10810.1016/j.matlet.2016.05.108 ↗
9. 10.1016/S0142-9612(03)00021-810.1016/S0142-9612(03)00021-8 ↗
10. 10.1016/j.ijpharm.2005.05.02710.1016/j.ijpharm.2005.05.027 ↗
11. 10.1016/j.addr.2008.09.00110.1016/j.addr.2008.09.001 ↗
12. 10.1016/j.ijpharm.2016.09.05310.1016/j.ijpharm.2016.09.053 ↗
13. 10.1016/j.cis.2014.03.00910.1016/j.cis.2014.03.009 ↗
14. 10.1016/j.ijpharm.2006.10.02410.1016/j.ijpharm.2006.10.024 ↗
15. 10.1021/la204944j10.1021/la204944j ↗
16. Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm. 2008;68:513–525.
17. 10.1016/j.carbpol.2008.02.00910.1016/j.carbpol.2008.02.009 ↗
18. 10.1080/21691401.2017.133905010.1080/21691401.2017.1339050 ↗
19. 10.1016/j.carbpol.2006.09.02710.1016/j.carbpol.2006.09.027 ↗
20. 10.1016/j.ijbiomac.2010.03.00410.1016/j.ijbiomac.2010.03.004 ↗
21. 10.1016/j.carbpol.2012.01.07010.1016/j.carbpol.2012.01.070 ↗
22. 10.1002/app.136510.1002/app.1365 ↗
23. 10.1016/j.msea.2007.01.03910.1016/j.msea.2007.01.039 ↗
24. 10.2147/IJN.S1759510.2147/IJN.S17595 ↗
25. 10.1016/j.ejpb.2006.08.00410.1016/j.ejpb.2006.08.004 ↗
26. 10.3109/21691401.2014.98667610.3109/21691401.2014.986676 ↗
27. 10.1002/app.3624310.1002/app.36243 ↗
28. 10.1016/j.snb.2008.02.04510.1016/j.snb.2008.02.045 ↗
29. 10.1007/s13204-012-0141-510.1007/s13204-012-0141-5 ↗
30. 10.4103/0250-474X.3943410.4103/0250-474X.39434 ↗
31. 10.1016/j.ijbiomac.2012.04.01810.1016/j.ijbiomac.2012.04.018 ↗
32. Yellanki SK, Singh J, Syed JA, et al. Design and characterization of amoxicillin trihydrate mucoadhesive microspheres for prolonged gastric retention. Int J Pharm Sci Drug Res. 2010;2:112–114.10.25004/IJPSDR.2010.020205 ↗
33. 10.1016/j.colsurfb.2010.11.03310.1016/j.colsurfb.2010.11.033 ↗
34. 10.3109/03639045.2014.94845210.3109/03639045.2014.948452 ↗
35. 10.2147/DDDT.S9773510.2147/DDDT.S97735 ↗
36. 10.1208/pt07037410.1208/pt070374 ↗
37. 10.1016/j.jcis.2014.12.03210.1016/j.jcis.2014.12.032 ↗
38. 10.3109/10717544.2014.91676910.3109/10717544.2014.916769 ↗
39. 10.1016/j.actbio.2009.03.00710.1016/j.actbio.2009.03.007 ↗
40. 10.1080/21691401.2017.130720710.1080/21691401.2017.1307207 ↗
41. Arora S, Budhiraja RD. Chitosan-alginate microcapsules of amoxicillin for gastric stability and mucoadhesion. J Adv Pharm Technol Res. 2012;3:68–74.10.4103/2231-4040.93555 ↗
42. 10.1016/j.foodhyd.2014.09.01510.1016/j.foodhyd.2014.09.015 ↗
43. 10.2147/DDDT.S10818510.2147/DDDT.S108185 ↗
44. 10.3109/10717544.2014.91498610.3109/10717544.2014.914986 ↗
45. 10.1002/app.2959210.1002/app.29592 ↗
46. 10.1016/S1381-5148(02)00168-210.1016/S1381-5148(02)00168-2 ↗
47. 10.1080/00914037.2013.76922910.1080/00914037.2013.769229 ↗
48. 10.1080/03602559.2012.66303510.1080/03602559.2012.663035 ↗
49. 10.1016/S0168-3659(02)00136-010.1016/S0168-3659(02)00136-0 ↗
50. 10.1016/j.msec.2008.07.03010.1016/j.msec.2008.07.030 ↗
51. 10.1016/j.carbpol.2010.06.00910.1016/j.carbpol.2010.06.009 ↗
52. 10.3109/21691401.2016.116371410.3109/21691401.2016.1163714 ↗
53. 10.1007/s11095-008-9763-410.1007/s11095-008-9763-4 ↗
54. 10.1080/13880209.2016.119443710.1080/13880209.2016.1194437 ↗
55. 10.1039/c3tb20487a10.1039/c3tb20487a ↗
56. 10.1016/j.ijbiomac.2012.06.00910.1016/j.ijbiomac.2012.06.009 ↗
57. 10.2147/IJN.S12429410.2147/IJN.S124294 ↗